Evgen Pharma PLC Investor presentation
17 Dicembre 2019 - 8:01AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
17 December 2019
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Investor presentation
Evgen Pharma (AIM: EVG) a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces it will hold an investor briefing on Tuesday,
14 January 2020.
The event will take place in the Copper Bar, upstairs at Balls
Brothers, 6 Adams Court, Old Broad St, London EC2N 1DX at 4.30pm
for a 4.45pm start. This will be followed by drinks and canapés,
and a chance to network. Dr Stephen Franklin, CEO and Richard
Moulson CFO, will provide a presentation on the Half Year Report
including an overview of the Company's strategy.
If you would like to register to attend the briefing, or require
further information, please contact Walbrook PR on 020 7933 8780 or
email evgen@walbrookpr.com.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Stephen Franklin, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0) 20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
WG Partners LLP +44 (0) 20 3705 9330
Nigel Barnes / Claes Spång
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage company developing sulforaphane
based medicines for the treatment of multiple diseases The
Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. Our lead
product, SFX-01, has demonstrated efficacy in a Phase II trial for
advanced metastatic breast cancer. It has been used to treat over
150 patients in clinical trials and is well-tolerated with
predominately mild side-effects.
Evgen shares are traded on the AIM market of the London Stock
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFMMMZVVZGLZM
(END) Dow Jones Newswires
December 17, 2019 02:01 ET (07:01 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024